Monoclonal Antibody Binding hACE2 Extracellular Domain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current efforts to develop effective therapeutics and prophylactics for SARS-CoV-2 infection have yielded limited success beyond vaccines, highlighting a need for innovative treatments that can specifically inhibit SARS-CoV-2 binding to human angiotensin converting enzyme 2 (hACE2) without impairing its normal functions.
Innovation Solution
Development of a monoclonal antibody that specifically binds to the extracellular portion of hACE2, inhibits SARS-CoV-2 binding, and does not significantly interfere with hACE2's ability to cleave angiotensin II or synthetic peptides, combined with recombinant AAV vectors for delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a monoclonal antibody binds to hACE2 to inhibit SARS-CoV-2 entry, then viral infection is prevented, but hACE2 enzymatic function may be impaired
Solution Approach 1:
The antibody is designed to bind to a specific local region (extracellular domain of hACE2) that is spatially separated from the enzymatic active site, allowing viral binding inhibition while preserving enzymatic function. The binding epitope is selected to be distinct from the catalytic domain where substrate cleavage occurs.
Solution Approach 2:
The monoclonal antibody acts as an intermediary that blocks the interaction between SARS-CoV-2 spike protein and hACE2 receptor, preventing viral entry without directly interfering with hACE2's enzymatic activity toward angiotensin II and other substrates.
2Adaptability or versatility
If broad-spectrum antiviral therapies are developed, then multiple virus types can be treated, but specificity to hACE2 function may be compromised
Solution Approach 1:
The antibody targets a conserved region of hACE2 that is essential for coronavirus entry across multiple variants, providing broad-spectrum protection. The binding site is selected to accommodate structural variations in viral spike proteins while maintaining consistent hACE2 recognition.
Solution Approach 2:
The patent employs computational modeling and structural biology approaches to identify and validate the antibody binding epitope, replacing traditional empirical screening methods with precision-guided rational drug design to achieve both specificity and broad applicability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The monoclonal antibody effectively reduces the likelihood of SARS-CoV-2 infection and provides therapeutic benefits by blocking viral entry into host cells without disrupting hACE2's normal enzymatic activities, as demonstrated by its ability to bind with high affinity and inhibit viral binding while maintaining hACE2's functional integrity.
Implementation Method 1
specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2)
Implementation Method 2
specifically inhibits binding of SARS-CoV-2 to the extracellular portion of hACE2
Implementation Method 3
the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA-based peptide
Data Source
AI summary
This invention provides a monoclonal antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically inhibits binding of SARS-CoV-2 to the extracellular portion of hACE2; and (iii) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA-based peptide. This invention also provides related recombinant AAV vectors, recombinant AAV particles, compositions, prophylactic and therapeutic methods, and kits.